Le Lézard
Classified in: Ebola virus, Health
Subject: ACC

Meda Aktiebolag Successfully Amends MTN Terms and Conditions and Exercises Call Option



SOLNA, Sweden, Dec. 6, 2017 /PRNewswire/ --

Meda Aktiebolag has successfully amended the terms and conditions of two series of notes issued pursuant to its SEK 7,000,000,000 medium term notes programme and inserted an early redemption call option which it will exercise with immediate effect

Today, Meda Aktiebolag (the "Company") held two noteholders' meetings pursuant to the summons sent on 7 November 2017 to the noteholders of the:

(i) SE0005132180 ? STIBOR 3M +2.85% 2013/2018 notes (the "2018 Notes"); and

(ii) SE0005991635 ? STIBOR 3M +1.65% 2014/2019 notes (the "2019 Notes" and together, with the 2018 Notes, the "Notes"),

issued under the SEK 7,000,000,000 medium term notes programme of the Company originally established on 25 May 2012 (as updated on 31 July 2012, 12 May 2014 and 16 July 2015), for the purposes of approving an amendment to the terms and conditions of the Notes to insert an early redemption call option (the "Call Option").

A sufficient number of noteholders were present in order for each noteholders' meeting to be quorate and a requisite majority of the voting noteholders at each noteholders meeting voted in favour of approving the proposed amendment to the terms and conditions.

As at the date hereof, the terms and conditions of the Notes have been effectively amended and the Company has given notice to the noteholders of each series of Notes that it will exercise the Call Option in accordance with the amended terms and conditions.

For further information regarding the amended terms and conditions and the Call Option, please refer to Skandinaviska Enskilda Banken AB (publ) acting as Tabulation and Paying Agent.

The Tabulation and Paying Agent:

 

Skandinaviska Enskilda Banken AB (publ)
Stjärntorget 4
SE-106 40 Stockholm
Sweden
Tel: +46 (0)8 763 80 96
Email: sebtenderagent@seb.se
Attention: SEB Tender Agent


 

The Board of directors
Meda Aktiebolag

For further inquiries, please contact:

Melissa Trombetta,
Head of Global Investor Relations
Mylan NV.
Tel: +1(917)262-2958
Melissa.Trombetta@mylan.com

This is information that Meda Aktiebolag is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 12:45 noon CET on 6 December 2017.

Meda Aktiebolag is a leading international specialty pharma company. Meda's products are sold in more than 120 countries worldwide and the company is represented by its own organizations in close to 60 countries. Find out more, visit www.meda.se.

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/meda/r/meda-aktiebolag-successfully-amends-mtn-terms-and-conditions-and-exercises-call-option,c2408816

The following files are available for download:

http://mb.cision.com/Main/357/2408816/763332.pdf

Press release (PDF)

 

SOURCE MEDA


These press releases may also interest you

17 aoû 2018
CHICAGO, August 17, 2018 /PRNewswire-PRWeb/ -- Healthy Interactions, a global leader in health education, in collaboration with Merck known as MSD outside the United States and Canada, today announced the launch of map4healthtm ? a digital platform...

17 aoû 2018
Healthy Interactions, a global leader in health education, in collaboration with Merck , known as MSD outside the United States and Canada, today announced the launch of map4healthtm ? a digital platform and mobile application in the U.S. that was...

17 aoû 2018
Eisai Inc. and Merck , known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved the kinase inhibitor LENVIMA® (lenvatinib) for the first-line treatment of patients with...

16 aoû 2018
Eisai Inc. and Merck , known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved the kinase inhibitor LENVIMA® (lenvatinib) for the first-line treatment of patients with...

16 aoû 2018
Hearing loss is the most common sensory disorder in the United States with more than 10 percent of Americans suffering from some impairment that affects their daily communication. Yet many people admit they don't often think about hearing loss and...

15 aoû 2018
Seven of Canada's top 10 cannabis patent holders are major multi-national pharmaceutical companies, according to a joint research project between Washington D.C. based New Frontier Data, the global authority in data, analytics, and business...




News published on 6 december 2017 at 07:16 and distributed by: